期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血清学标志物在乳腺癌诊治中的应用(文献综述) 被引量：2

下载PDF
导出
作者 盛世乐 黄钢
机构地区 上海交通大学医学院附属仁济医院
出处 《放射免疫学杂志》 CAS 2006年第5期414-417,共4页 Journal of Radioimmanology
基金 国家自然科学基金资助项目(30470497) 上海市科委重点基金资助项目(02DJ04137)
关键词 乳腺癌早期诊断 血清学标志物 文献综述 组织多肽特异性抗原 RECEPTOR HER-2 肿瘤标志物 诊治
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献40

  • 1Michael J.Duffy.Serum tumor markers in breast cancer:are they of clinical value? Clinical Chemistry.2006,52:3345.
  • 2Bosl GJ,Motzer RJ.Testicular germ-cell cancer.N Engl J Med.1977,337:242.
  • 3Duffy MJ.CA15-3 and related mucins ad circulating markers in breast cancer.Ann Clin Biochem.1999,36:579.
  • 4Cheung K,Graves CRL,Robertson JFR.Tumour marker measurements in the diagnosis and monitoring of breast cancer.Cancer Treat Rev.2000,26:91.
  • 5Nicolini A,Carpi A.Postoperative follow-up of breast cancer patients:overview of progress in the use of tumor markers.Tumor Biol.2000,21:235.
  • 6Price MR,Tendler JB.Polymorphic epithelial mucins (PEM):molecular characteristic and association with breast cancer.Breast.1993,2:3.
  • 7Von Mensdorff-Pouilly S,Snijdewint FGM,Verstraeten AA,et al.Human MUC1 mucin:a multifacted glycoprotein.Int J Biol Markers.2000,15:343.
  • 8Hayes D,Sekine H,Ohao T,et al.Use of murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.J Clin Invest.1985,75:1671.
  • 9Hayes DF,Zurawski VR,Kufe DW.Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.J Clin Oncol.1986,10:1542.
  • 10Reddish MA,Helbrecht N,Almeida AF,et al.Epitope mapping of Mab B27.29 within the protein core of the malignant breast carcinoma-associated mucin antigen MUC1.J Tumor Marker Oncol.1992,7:19.

同被引文献47

  • 1郑航,罗荣城.TPS、CA-153和CEA联合检测对乳腺癌的诊断价值[J].第一军医大学学报,2005,25(10):1293-1294. 被引量：46
  • 2A1-Joudi F S, Kaid F A, Ishak I, et al. Expression of human mammaglobin and clinicopathologic correlations in breast can-cer: the findings in Malaysia[J]. Indian J Pathol Microbiol, 2011,54(2):284-289.
  • 3Duffy M J. Serum tumor markers in breast cancer: are they of clinical value[J]? Clin Chem, 2006,52(3):345-351.
  • 4Kadowaki M, Sangai T, Nagashima T, et al. Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach[J]. J Cancer Res Clin Oncol, 2011,137(7):1105-1115.
  • 5Scanlon E F. Progress in the treatment of early breast cancer [J]. Cancer, 1990,65(9 Suppl):2110-2112.
  • 6Dupont W D, Parl F F, Hartmann W H, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia[J]. Cancer, 1993,71(4):1258-1265.
  • 7Felding-Habermann B, Cheresh D A. Yitroneetin and its re- ceptors[J]. Curr Opin Cell Biol, 1993,5(5):864-868.
  • 8Hess S, Kanse S M, Kost C, et al. The versatility of adhe- sion receptor ligands in haemostasis:morpho-regulatory func- tions of vitronectin[J]. Thromb HaemosL 1995,74(1):258-265.
  • 9Preissner K T, Seiffert D. Role of vitroneetin and its recep- tors in haemostasis and vascular remodeling[J]. Thromb Res, 1998,89(1):1-21.
  • 10Huai Q, Zhou A, Lin L, et al. Crystal structures of two hu- man vitronectin, urokinase and urokinase receptor complexes [J]. Nat Struct Mol Biol, 2008,15(4):422-423.

引证文献2

二级引证文献6

放射免疫学杂志
2006年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部